LIX expands feline cannabinoid line with advanced formula elixir
Bottom line
LIX Pet Wellness has added a second feline cannabinoid product to its lineup with the launch of Advanced Formula: Feline, an ELIXIR aimed at cats already using CBD and needing broader daily support. The product combines 300 mg of CBD, 200 mg of CBG, and 100 mg of CBN in organic MCT coconut oil, using what the company describes as a 3:2:1 cannabinoid profile for cats under 30 pounds. The launch builds on LIX’s existing feline tincture and extends an “Advanced Formula” platform the company has already used in other products and species. (petretailnews.com)
Why it matters: For veterinary professionals, the launch is another sign that multi-cannabinoid products are moving deeper into the companion animal supplement market, especially for senior support, mobility, sleep, appetite, and stress-related positioning. But it also lands in a regulatory gray zone: FDA says there are no approved hemp-derived ingredients listed for animal food and no FDA-approved cannabis-containing products for animal use, while the agency has continued to seek more veterinary input on usage trends, safety concerns, adverse events, and potential drug interactions. That means clinics can expect more questions from pet parents, even as evidence, product standardization, and regulatory clarity remain limited. (fda.gov)
What to watch: Watch for whether LIX expands retail distribution or publishes more product-specific data, and whether FDA’s ongoing interest in veterinary cannabis-derived products leads to clearer guardrails for practice discussions and product claims. (fda.gov)
LIX Pet Wellness is expanding its feline portfolio with Advanced Formula: Feline, a new ELIXIR formulated for cats that are already using CBD and are positioned by the company as needing a higher level of daily wellness support. According to company and trade coverage, the product contains 300 mg CBD, 200 mg CBG, and 100 mg CBN in organic MCT coconut oil, with dosing designed for cats under 30 pounds. (petretailnews.com)
The launch appears to be a line extension rather than a category entry. LIX already sells a Feline ELIXIR tincture for cats and small animals, marketed as flavorless, odorless, THC-free, and made with broad-spectrum hemp extract in MCT oil. The company has also been building out an “Advanced Formula” range in other formats, including BITES, and has described that platform as intended for pets already on a CBD routine, senior pets, and animals with more advanced support needs. (lixpetwellness.com)
In practical terms, the new feline product gives LIX a step-up option for repeat users rather than asking pet parents to jump from a standard CBD tincture to a general small-dog formula. Trade reporting says the move follows strong sales of the company’s original Feline ELIXIR. The formulation also mirrors LIX’s broader push around a 3:2:1 CBD:CBG:CBN ratio, which the company has promoted across its advanced products for support tied to cognition, mobility, inflammation, sleep, appetite, and stress. Those are common consumer demand areas in senior-pet wellness, even though the evidence base for specific combinations and indications in cats remains limited. (petretailnews.com)
LIX’s own messaging around the broader Advanced Formula line emphasizes observed results in senior animals, especially around cognition, engagement, physical comfort, and sleep, according to a prior company press release on its BITES launch. What’s missing so far is publicly available, product-specific clinical data for this feline formula. I did not find a peer-reviewed study or regulatory filing tied specifically to Advanced Formula: Feline in the available source material, which is notable given how heavily pet cannabinoid marketing still relies on formulation logic, anecdotal response, and brand-level positioning. (lixpetwellness.com)
From an industry perspective, the bigger story may be less about one SKU and more about where the market is heading. The National Animal Supplement Council says its Quality Seal program is meant to elevate and standardize the animal supplement category through manufacturing, labeling, and adverse-event oversight, and NASC has also highlighted tolerability work in dogs involving CBD and CBD-plus-CBG products. Still, quality programs are not the same as FDA approval or proof of efficacy, and available cannabinoid safety and efficacy data remain much stronger in dogs than in cats. (nasc.cc)
Why it matters: For veterinary teams, products like this are likely to drive more nuanced conversations with pet parents about what “advanced support” actually means, how to assess concurrent medications, and where supplement claims outpace evidence. FDA states that there are no approved cannabis-containing products for animal use and no approved hemp-derived ingredient definitions for animal food, while also signaling that it wants more information from veterinarians on indications, benefits, safety problems, toxicology, and drug interactions. In other words, the market is advancing faster than the regulatory and clinical framework around it. (fda.gov)
That gap matters operationally. Clinics may increasingly see pet parents arrive with products already in hand, especially for aging cats with mobility issues, sleep disruption, appetite changes, or stress-related concerns. The veterinary opportunity is not necessarily to endorse every product category claim, but to guide safer discussions around dosing consistency, ingredient transparency, THC exposure risk, adverse-event monitoring, and when a supplement conversation may be masking a condition that needs a full medical workup. FDA has also continued enforcement against some companies making animal CBD claims, underscoring how sensitive the claims environment remains. (fda.gov)
What to watch: Next, watch for broader distribution, any third-party testing or clinical data LIX chooses to publish, and whether federal regulators move from information-gathering toward clearer policy on cannabis-derived products in veterinary medicine after the agency’s January 16 to April 16, 2025 request for information. (fda.gov)